India’s upcoming semaglutide boom: A turning point for GLP‑1 drugs, pricing and patient access Biplab Lenin and Priyam Rajkumar Mar 18, 2026 With semaglutide’s Indian patent set to expire on March 20, 2026, domestic drugmakers are preparing to enter the GLP‑1 market,…
WHO issues warnings on fake copies of Novo Nordisk’s weight-loss drugs Reuters Jun 21, 2024 The warnings were issued on fake drugs claiming to contain the active ingredient found in Novo Nordisk's diabetes drug Ozempic…
